Neuralink Files for $649M Equity Offering to Advance The Link and Blindsight BCI Platforms

June 12, 2025Brain-Computer Interface Company NeuralinkFiling documents with the U.S. Securities and Exchange Commission (SEC),Proposed Financing through Equity Issuance$649 million(approximately RMB 4.7 billion)，The funds will primarily be used to advance the clinical validation of its implantable brain-computer interface product, The Link, and the development of its second-generation product, Blindsight.

This marks the company’s second major fundraising effort following the completion of its $600 million Series E financing in May, signaling its formal entry into a critical phase focused on product validation and commercialization.

# Two Rounds of Financing in One Month, Valuation Stabilized at $9 Billion

Neuralink’s fundraising pace has accelerated significantly over the past year. The current equity offering plan reveals that Neuralink has secured $124 million from 12 undisclosed investors. If this fundraising round is successfully completed, the company will add $649 million to its cash reserves, laying the foundation for advancing global clinical trials and product engineering.

Combined with the previously completed Series E financing, Neuralink’s total fundraising in the capital markets this year has exceeded$1.2 billion.

According to multiple foreign media outlets, Neuralink’s pre-money valuation for this financing round was approximately$9 billion, surpassing the $8 billion valuation during secondary market transactions in July 2024 and the approximately $5 billion valuation in private equity transactions in 2023. Its valuation doubled within one year.

Neuralink's Funding Milestones in Recent Years:

• July 2021 Series C Financing: $205 million, led by Founders Fund, Google Ventures, and others;
• August 2023 Series D Financing: $280 million;
• November 2023 Supplemental Financing: $43 million;
• May 2025 Series E Financing: $600 million, pre-money valuation of $9 billion; (Link:$4.3 Billion in Financing! Brain-Computer Interface Unicorn’s Valuation Soars to $65 Billion!）
• June 2025 Equity Issuance Filing: Seeking to raise $649 million in financing.

The continued growth in financing volume and valuation indicates that Neuralink has garnered high expectations from the capital market regarding its product potential and R&D roadmap.

# Technical Platform Architecture: N1×R1 Builds a Closed-Loop Neural Control System

Neuralink’s core product consists of two key components:N1 ImplantandR1 Surgical Robot。

N1 Implant: Flexible Microelectrodes and Wireless Communication

N1 is a highly integrated neural signal acquisition and transmission device, with its design centered around three core pillars: long-term implantation, tissue compatibility, and signal stability.

• Structural Design: The N1 implant measures approximately 23 mm × 8 mm and features a compact structure. Its 64 ultra-fine flexible threads embed 1,024 electrode contacts, offering high spatial density and tissue compliance.
• Biocompatible Materials: The device is encapsulated in bioinert materials to avoid immune rejection and support long-term implantation.
• Wireless Charging and Data Transmission: No external opening is required; the battery is charged via an external skin-mounted device, and neural signals are transmitted to the terminal through a low-power wireless module.

The key breakthrough of this structure lies in:

• The electrode density is significantly higher than that of traditional Utah arrays and Neuropixels technology;
• Flexible threads conform to the three-dimensional curvature of the brain surface, reducing tissue damage caused by micromotion;
• The system features long-term stable signal acquisition and data processing capabilities, supporting real-time translation of neural intentions.
  

N1 System IncludesLow-Power Processing Chip, it can perform preliminary filtering and encoding of the signal, transmitting neural signals in real time to the Neuralink application via a wireless module. This application integrates proprietary neural decoding algorithms capable of converting neural electrical activityConvert into "action intent" or "control signals", applied to external terminals such as computers, robotic arms, and wheelchairs.

The current system has implemented controls for cursor movement, web browsing, and interactive mini-games, with the future goal of expanding to full-function peripheral device control and multi-modal human-computer interaction.

R1 Surgical Robot: Millimeter-Level Precision Operation Platform

The R1 surgical robot is an automated operating platform designed to address the challenges of flexible thread implantation.

• Equipped withFive Sets of Cameras and OCT Imaging System, real-time monitoring of the brain surface structures and vascular course can be performed intraoperatively;
• Use high-frequency microneedles to implant each thread individually into the dermis, avoiding blood vessels to ensure precision and safety;
• Automated processes enhance surgical efficiency and reduce human error.

The robot and the implant form a closed-loop system, with intraoperative image guidance, postoperative data collection, and real-time decoding functions working in close coordination, marking that Neuralink has initially established an integrated BCI clinical platform.

# Advancing Clinical Pathways: Multi-Country Trials + Product Stratification Strategy

Neuralink currently has two main product pipelines entering the human research phase:

Telepathy System: A Mind-Control Platform for Paralyzed Patients

Telepathy is a brain-computer interface (BCI) developed by Neuralink, designed to help paralyzed patients (such as those with quadriplegia due to spinal cord injury or amyotrophic lateral sclerosis) control external devices—such as computer cursors, keyboards, or mobile phones—through thought, thereby restoring a degree of autonomy.

• May 2023: Received FDA approval to conduct the first-in-human trial (PRIME);
• January 2024–April 2025: Completed implantation in three patients;
• November 2024: Health Canada approves the CAN-PRIME study;
• 2025 Plan: Expand to 20–30 subjects to establish stability and safety data.
  

As of early 2025, the three participants had cumulatively used the device for over 4,900 hours, with a total implantation duration exceeding 670 days. The device was primarily used for tasks such as cursor control, web browsing, and game interaction, and patient feedback has been positive.

Blindsight System: A Visual Stimulation Device for the Blind

In October 2024, Neuralink’s Blindsight system received the FDA “Breakthrough Device” designation. It helps patients with damaged visual pathways restore light perception by directly stimulating the visual cortex via electrodes.

The first-generation product can generate simple light spots in the patient's field of vision, while subsequent versions aim to enhance stimulation resolution and the structural perception of visual patterns, providing basic sensory function for blind patients.

This pathway bypasses conventional imaging routes such as the eyeball and optic nerve, representing a significant breakthrough direction for brain-computer interfaces (BCIs) in sensory restoration.

# Competitive Landscape: Coexistence of Invasive and Non-Invasive Approaches

Neuralink’s defining feature is its invasive, high-density implantation approach, which offers advantages in sampling rate, signal stability, and control precision. However, this approach also entails high risks and significant barriers to entry.

Current Layout of Major Companies in the Same Field:

• Synchron：Transcatheter Implantation, featuring minimally invasive advantages, and has completed patient trials in the United States and Australia;
• Precision Neuroscience: From former Neuralink employees, utilizing surface thin-film electrodes, emphasizingReversibility and Low Invasiveness;
• Blackrock Neurotech: Focusing on research applications, establishing academic experimental platforms and customized equipment.

Neuralink leads in hardware integrity and surgical automation, but its complex procedures, high implantation costs, and significant ethical risks entail greater reliance on clinical centers and pose higher barriers to short-term commercialization.

# Ethical Oversight: Challenges in Safety, Animal Testing, and Data Transparency

Neuralink has been subject to multiple regulatory investigations in recent years:

• Since 2022, the U.S. Department of Agriculture investigated animal welfare issues, alleging that experimental monkeys suffered paralysis and cerebral edema during electrode implantation;
• November 2023, the SEC intervened to investigate whether its information disclosure was adequate;
• December 2024, Musk issued a lawyer's letter stating that the SEC has reopened relevant proceedings.

Although Neuralink emphasizes that there have been no cases of animal deaths directly caused by the device, its approach, which requires penetration of brain tissue, remains highly sensitive from an ethical standpoint.

When advancing toward final FDA approval in the future, how regulatory requirements are met across dimensions such as data transparency, ethical validation, and long-term follow-up will directly determine its market pace.

Although Neuralink currently focuses primarily on the U.S. market, globally, some countries and regions have begun exploring pathways to incorporate brain-computer interfaces (BCIs) into their healthcare insurance systems, attempting to set medical service prices for procedures such as implantation, usage, and adaptation. These trends indicate that BCIs are gradually moving beyond the realm of scientific research and entering the early stages of healthcare service pricing and regulatory agendas.
For Neuralink, surgical standardization, device stability, and compatibility with insurance systems will be indispensable factors for achieving large-scale application in the future.

# Neuralink Advances to a Critical Phase Toward a “Verifiable Closed-Loop Platform”

Two consecutive rounds of substantial financing and a global clinical layout indicate that Neuralink is in a transitional phase between “prototype breakthrough” and “establishment of standard pathways.” Its true competitiveness lies not only in the implantable device itself, but also in:

• Whether a standardized and automated surgical procedure platform can be established;
• Whether it can provide a long-term stable signal and user interface;
• Whether it can overcome the three barriers of ethics, regulation, and payment to complete closed-loop validation.

Amid the global BCI industry’s growing trend toward “platformization,” Neuralink is one of the few players currently capable of end-to-end product integration. Over the next decade, its development trajectory will profoundly shape the establishment of standards and the construction of clinical applications in the invasive brain–computer interface sector.

Its position at the forefront also means that it must first address:

• Is High-Density Implantation Safe and Controllable?
• Can the implantation procedure be standardized and replicated?
• Is the cost of use acceptable?
• Is the system ecosystem scalable?

This may well be the underlying logic behind investors’ continued capital infusion: what they are betting on is not a single device, but a verifiable closed-loop neural interface system.